0001062993-23-016695.txt : 20230817 0001062993-23-016695.hdr.sgml : 20230817 20230817160832 ACCESSION NUMBER: 0001062993-23-016695 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230815 FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Geist William CENTRAL INDEX KEY: 0001832210 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 231181940 MAIL ADDRESS: STREET 1: 900 MIDDLESEX TURNPIKE STREET 2: C/O QUANTERIX CORPORATION CITY: BILLERICA STATE: MA ZIP: 01821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-08-15 0000842023 BIO-TECHNE Corp TECH 0001832210 Geist William 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 0 1 0 0 PRESIDENT, PROTEIN SCIENCES 0 Common Stock 9960 D Restricted Stock Units Common Stock 7140 7140 D Stock Options (Right to Buy) 94.52 2029-08-15 Common Stock 22200 22200 D Stock Options (Right to Buy) 94.52 2029-08-15 Common Stock 29600 29600 D Restricted Stock Units Common Stock 3360 3360 D Stock Options (Right to Buy) 100.39 2029-02-01 Common Stock 11936 11936 D Stock Options (Right to Buy) 100.39 2029-02-01 Common Stock 15912 15912 D Restricted Stock Units 2023-08-15 4 A 0 8377 0 A Common Stock 8377 8377 D Stock Options (Right to Buy) 84.61 2023-08-15 4 A 0 22544 0 A 2030-08-15 Common Stock 22544 22544 D Stock Options (Right to Buy) 84.61 2023-08-15 4 A 0 30059 0 A 2030-08-15 Common Stock 30059 30059 D Represents 6,640 shares of restricted stock for which the risk of forfeiture will lapse as to 3,320 shares on each of February 1, 2024 and February 1, 2025. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026. Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 3,976 shares vest on each of 2/1/2025 and 2/1/2026. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026. On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split. /s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed 2023-08-17